Vimarsana
Biggest News Aggregation in the World

Page 4 - Between Oct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Between Oct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Between Oct Today - Breaking & Trending Today

Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia - Vimarsana News

Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia

1. Median time to sinus conversion was 17.2 minutes in the etripamil group versus 53.5 minutes in the placebo group. 2. Twice as many patients in the etripamil group converted to sinus rhythm than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Symptomatic supraventricular tachycardia (SVT) can cause severe distress to patients. Current management includes

#VisualAbstract: Cognitive functional therapy, with or without movement sensor biofeedback, improves chronic low back pain - Vimarsana News

#VisualAbstract: Cognitive functional therapy, with or without movement sensor biofeedback, improves chronic low back pain

1. Patients assigned to cognitive functional therapy (CFT) reported improved quality-adjusted life-years versus usual care. 2. Both CFT groups were found to have significantly reduced societal costs compared to the usual care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Chronic low back pain is the leading cause of disability worldwide. Cognitive functional therapy (CFT) is

Related Topics:
Between Oct
Cognitive functional therapy, with or without movement sensor biofeedback, improves chronic low back pain - Vimarsana News

Cognitive functional therapy, with or without movement sensor biofeedback, improves chronic low back pain

1. Patients assigned to cognitive functional therapy (CFT) reported improved quality-adjusted life-years versus usual care. 2. Both CFT groups were found to have significantly reduced societal costs compared to the usual care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Chronic low back pain is the leading cause of disability worldwide. Cognitive functional therapy (CFT)

Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer - Vimarsana News

Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer

1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). 2. Treatment-related adverse events were comparable among patients in either group. Evidence Rating Level: 1 (Excellent) Study Rundown: Biliary tract cancers are a complex group of epithelial tumors with a poor prognosis. The first-line therapy

'Aviva hiked my parents' equity release fee from £2,000 to £12,000 overnight' - Vimarsana News

'Aviva hiked my parents' equity release fee from £2,000 to £12,000 overnight'

Homeowners are increasingly turning to equity release – but such deals can be risky